Psychiatric symptoms during interferon treatment for hepatitis C: Experiences from a tertiary care hepatology centre

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 11, 2008, Pages 1071-1080

  Evon, D M ^a   Verma, A ^a   Simpson, K ^a   Galanko, J A ^a   Dougherty, K A ^a   Fried, M W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CITALOPRAM; FLUOXETINE; PAROXETINE; PEGINTERFERON; RIBAVIRIN; SERTRALINE;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ANGER; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STANDARD; SUBSTANCE ABUSE; SURVIVAL RATE; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 42949139729     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03640.x     Document Type: Article

References (33)

1. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002 36 (5 Suppl. 1 S121 7.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 26 : 347.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
4. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997 26 (3 Suppl. 1 112S 21S.
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 (5 Suppl. 1 S237 44.
6. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000 18 : 2316 26.
7. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000 31 : 1207 11.
8. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005 66 : 41 8.
9. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002 7 : 942 7.
10. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003 64 : 708 14.
11. Rifai MA, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol 2006 9 : 508 19.
12. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003 44 : 104 12.
13. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000 157 : 867 76.
14. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000 18 : 107 16.
15. Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 2004 33 (Suppl. 1 S35 50.
16. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005 19 : 105 23.
17. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005 19 : 23 7.
18. Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005 10 : 332 3.
19. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007 52 : 3251 8.
20. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999 354 : 131 2.
21. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005 42 : 793 8.
22. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002 22 : 86 90.
23. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004 22 : 365.
24. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006 26 : 655 62.
25. El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002 123 : 476 82.
26. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002 97 : 1813 20.
27. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007 102 : 2426 33.
28. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005 12 : 81 5.
29. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002 97 : 149 55.
30. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002 34 : 268 71.
31. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006 44 : 491 8.
32. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007 63 : 131 5.
33. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004 82 : 175 90.